Click chemistry joins small reactive molecular building blocks together to drive binding reactions.
Deal for anti-inflammatory candidate includes access to back-up antibodies.
In this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.
The hygiene hypothesis—or more recently dubbed microbiome depletion theory—is a supposition proposed in the late 1980s from the observation that children in larger family...
University of Toronto devise electrochemical phenotyping approach to rapidly detect antibiotic-resistant bacteria.
Mice injected with recombinant Pfs25 protein generate parasite transmission-blocking antibodies.
Scientists have developed a high-throughput artificial intelligence-based imaging technique that can automatically screen for subtle morphological changes associated with genetic manipulation in Caenorhabditis elegans nematodes.
RNAi decreases expression of sFLT1, the cause of preeclampsia symptoms, establishing a potential strategy for the treatment of preterm preeclampsia.
Merck & Co. will partner with Taiho Pharmaceutical and Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical, to develop small molecule inhibitors against the KRAS oncogene and several other drug targets under study as potential cancer treatments, through a collaboration that could generate more than $2.5 billion for Taiho and Astex.
Endocyte has licensed ABX’s radioligand therapeutic (RLT) candidate PSMA-617 in a deal that could generate up to $172 million-plus for the German nuclear medicine company, adding that it will refocus the company’s development efforts around the prostate cancer treatment.